接受辅助生殖技术夫妇接种新冠灭活疫苗的安全性与有效性:前瞻性队列研究
该前瞻性队列研究纳入2021年8月至2022年9月在四川锦欣西囡妇女儿童医院接受体外受精治疗的夫妇,按卵巢刺激前是否接种新冠灭活疫苗分为接种组和未接种组,经倾向性评分匹配后比较实验室参数与妊娠结局。结果显示接种组与未接种组女性活产率、临床妊娠率、生化妊娠率及持续妊娠率均无显著差异,男性接种对辅助生殖技术妊娠结局无影响,夫妇接种对胚胎发育和妊娠结局亦无显著影响。作者建议夫妇按计划接种新冠疫苗以助力疫情防控。
要点
- 经倾向性评分匹配后,接种组与未接种组女性活产率分别为41.23%和44.08%,差异无统计学意义(P=0.555)。
- 两组临床妊娠率、生化妊娠率及持续妊娠率均无显著差异(P分别为0.625、0.762、0.770)。
- 男性接种及夫妇双方接种对辅助生殖技术妊娠结局和胚胎发育均无显著影响(所有P>0.05)。
核心结论
- 研究结果表明,新冠疫苗接种对接受新鲜胚胎移植的体外受精/卵胞浆内单精子注射患者无显著影响。
- 作者建议夫妇按计划接种新冠疫苗,以帮助减轻新冠大流行。
研究设计与样本
- 前瞻性队列研究,纳入2021年8月至2022年9月在四川锦欣西囡妇女儿童医院接受体外受精治疗的夫妇。
- 根据卵巢刺激前是否接种疫苗分为接种组和未接种组,比较两组实验室参数和妊娠结局。
- 采用倾向性评分匹配(PSM)后进行分析。
主要发现
- 经PSM后,接种组与未接种组女性活产率分别为41.23%和44.08%(P=0.555),临床妊娠率分别为52.61%和54.98%(P=0.625),生化妊娠率分别为62.56%和63.98%(P=0.762),持续妊娠率分别为49.76%和51.18%(P=0.770),均无显著差异。
- 两组胚胎发育和实验室参数无显著差异。
- 男性接种对辅助生殖技术治疗患者的妊娠结局无影响(所有P>0.05)。
- 夫妇接种对辅助生殖技术胚胎发育和妊娠结局无显著影响(所有P>0.05)。
临床怎么用
- 原文未据此给出具体临床推荐,仅作者在结论中建议夫妇按计划接种新冠疫苗以帮助减轻新冠大流行。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The safety of the COVID-19 inactivated vaccine on pregnancy outcomes in couples undergoing assisted reproductive technology remains uncertain due to limited and speculative evidence. Existing studies primarily focus on the vaccination status of females, with scant information available regarding the vaccination status of male partners. Moreover, there is minimal research tracking live birth outcomes. OBJECTIVE(S): The objective of this study was to evaluate the impact of COVID-19 inactivated vaccine administration on the outcomes of in vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI) cycles in infertile couples in China. METHODS: This prospective cohort study involved couples undergoing IVF treatment at Sichuan Jinxin Xinan Women & Children's Hospital from August 2021 to September 2022. Based on whether they received vaccination before ovarian stimulation, the couples were divided into the vaccination group and the non-vaccination group. We compared the laboratory parameters and pregnancy outcomes between the two groups. RESULTS: After performing propensity score matching (PSM), we observed similar live birth rates (41.23% vs. 44.08%, P = 0.555), clinical pregnancy rates (52.61% vs. 54.98%, P = 0.625), biochemical pregnancy (62.56% vs. 63.98%, P = 0.762), and ongoing pregnancy rates (49.76% vs. 51.18%, P = 0.770) between the vaccinated and unvaccinated women. Also, no significant disparities were found in terms of embryo development and laboratory parameters between the groups. Moreover, male vaccination had no impact on patients' pregnancy outcomes in assisted reproductive technology (ART) treatments (all P > 0.05). Additionally, there were no observable effects of vaccination on embryo development and pregnancy outcomes among couples undergoing ART (all P > 0.05). CONCLUSION(S): The findings suggest that COVID-19 vaccination did not have a significant effect on patients undergoing IVF/ICSI with fresh embryo transfer. Therefore, it is recommended that couples should receive COVID-19 vaccination as scheduled to help mitigate the COVID-19 pandemic.
引用
- Yang J, Yao YL, Lv XY, et al. The Safety and Efficacy of inactivated COVID-19 vaccination in couples undergoing assisted reproductive technology: A prospective cohort study. Vaccine. 2024. PMID: 39708514. doi:10.1016/j.vaccine.2024.126635
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。